These results advance our understanding of the link between one of the most promising fluid biomarker of neurodegeneration in FTD and the pathological process occurring in this condition and further support the application of blood-derived NfL concentration as a noninvasive biomarker for application in a clinical setting and in treatment trials. This evidence concerns the gene NEFL and frontotemporal dementia.